While improvements in asthma treatment have come on in leaps and bounds, common sense suggests that a drug that works for one person may not do as much good for others. Now new research is beginning to shed light on the reasons why, as doctors learn more about the differences in how diverse patients metabolize asthma medicines.
Asthma is not a uniform disorder. It can occur in different ways and where some of the features of the disease like inflammation allergy immune activity and lung function may differ from person to person. Genetics seem to play a part here too, and it is now being thought that the same genetic variation may one day be used to decide, which treatments will work better for certain patients.
2016 Study TheJournal of the Allergy & Clinical Immunology published this 2026studying delay genetic effects on specific asthma subtypes. Researchers found genetic signatures specific to various endotypes of asthma, including those linked to type 2 inflammation and allergicness. The research also found genetic interactions of gene by drug-relevant pathway interactions, raising hope that in the future genetic features can support more targeted therapies.
In one other research of youngsters with excessive asthma taking the biologic drug omalizumab that focuses on the immune system’s immunoglobulin E or IgE, researchers checked out a choose of genetic variations in 30 youngsters. They discovered some genetic variations have been related to adjustments in lung operate, fewer episodes of extreme wheezing, and fewer use of oral steroids but the scientists stated their findings have been “exploratory, ” and that larger scientific trials might want to be completed to qualify these genetic markers for scientific use.
The concept of genetics influencing treatment response in asthma is not a new one. Previous studies have pinpointed specific genetic variations that influence response to inhaled corticostroids. In such studies, for instance, the European study of the GLCCI1 gene identified genetic variants that predicted a decreased lung-function response to inhaled glucocorticoids. Studies on potential more genes and pathways involved in response continue to be published.
Pharmacogenomics is an area of research that explores how a person’s genes can affect the way they react to medicines. For asthma, pharmacogenetics research may, in time, enable doctors to determine, which patients are more likely to respond to a specific treatment.
In theory, the effects could be far-reaching. Many treatments are tailored as a patient’s progress during use; based on symptoms, lung functions and response to testing, modifications to dosages are made. If it is possible for a doctor to accurately determine a person’s response, they could more accurately select the optimal treatment rather than having to test the options.
Still, scientists warn that “it’s a work in progress” and that a treatment response gene in one study is not necessarily suitable for clinical testing. Replication studies must be carried out in larger and more heterogeneous populations, and researchers have to work out how the genetic factors they have identified interact with environmental exposures, disease severity and other biological traits.
They find that exploring asthma might involve looking not just at symptoms and common clinical measurements, but at genetic and molecular nuances that will always make each patient’s disease inherently different.
